CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-293-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10 million
Profitability
Miscellaneous
Employees43
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions
What is CymaBay Therapeutics' stock symbol?
CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
How were CymaBay Therapeutics' earnings last quarter?
CymaBay Therapeutics Inc (NASDAQ:CBAY) announced its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.02. View CymaBay Therapeutics' Earnings History.
When is CymaBay Therapeutics' next earnings date?
What price target have analysts set for CBAY?
12 analysts have issued 12-month price targets for CymaBay Therapeutics' shares. Their predictions range from $7.00 to $22.00. On average, they expect CymaBay Therapeutics' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 148.7% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics.
What is the consensus analysts' recommendation for CymaBay Therapeutics?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CymaBay Therapeutics.
What are Wall Street analysts saying about CymaBay Therapeutics stock?
Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
- 1. HC Wainwright analysts commented, "916-3963, Rating POS Risk-adj value Full value Shares outstanding 68,696 S/O as of April 30, 2019. Current share price $6.05 Discount rate 20.0% Seladelpar (PBC) – U.S." (6/12/2019)
- 2. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (5/14/2019)
- 3. Cantor Fitzgerald analysts commented, ". Reiterate our Overweight rating; increasing 12-mo. PT to $20. CymaBay is a liver disease company with lead asset, seladelpar, in Ph3 for primary biliary cholangitis (PBC). Our checks suggest seladelpar’s strong profile in PBC has the potential to grow the market significantly from where it is today. We think the opportunity in PBC alone (~$350M in 2026 unadjusted sales vs. cap of $500M) should justify upside. We see further potential for seladelpar with a 2Q19 Ph2b NASH proof of concept readout, which could be a much larger opportunity (~ $4B+) for Seladelpar if successful. In our 75-page slide deck, we took a close look at PPAR-delta biology & role in NASH. Our Take: PPAR-delta has the potential to be a major target in the NASH space." (2/1/2019)
Has CymaBay Therapeutics been receiving favorable news coverage?
News articles about CBAY stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CymaBay Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for CymaBay Therapeutics.
Who are some of CymaBay Therapeutics' key competitors?
Some companies that are related to CymaBay Therapeutics include Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), G1 Therapeutics (GTHX), Enanta Pharmaceuticals (ENTA), Gossamer Bio (GOSS), Radius Health (RDUS), Theravance Biopharma (TBPH), Opko Health (OPK), AnaptysBio (ANAB), BELLUS Health (BLUSF), Ra Pharmaceuticals (RARX) and Innoviva (INVA).
What other stocks do shareholders of CymaBay Therapeutics own?
Who are CymaBay Therapeutics' key executives?
CymaBay Therapeutics' management team includes the folowing people:
- Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)
- Mr. Daniel Menold, VP of Fin. (Age 49)
- Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)
- Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)
- Dr. Pol F. Boudes, Chief Medical Officer (Age 62)
Who are CymaBay Therapeutics' major shareholders?
CymaBay Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.05%), Perceptive Advisors LLC (5.62%), Vanguard Group Inc. (5.18%), Eagle Asset Management Inc. (4.04%), Vivo Capital LLC (3.14%) and Rock Springs Capital Management LP (1.31%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Daniel Menold, Kurt Von Emster and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.
Which institutional investors are selling CymaBay Therapeutics stock?
CBAY stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Versant Venture Management LLC, UBS Asset Management Americas Inc., Perceptive Advisors LLC, JPMorgan Chase & Co., Eagle Asset Management Inc., Marshall Wace North America L.P. and Wells Fargo & Company MN. Company insiders that have sold CymaBay Therapeutics company stock in the last year include Carl Goldfischer and Kurt Von Emster. View Insider Buying and Selling for CymaBay Therapeutics.
Which institutional investors are buying CymaBay Therapeutics stock?
CBAY stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, University of Notre Dame DU Lac, Vanguard Group Inc., D. E. Shaw & Co. Inc., Rock Springs Capital Management LP, Invesco Ltd. and Vivo Capital LLC. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.
How do I buy shares of CymaBay Therapeutics?
Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CymaBay Therapeutics' stock price today?
One share of CBAY stock can currently be purchased for approximately $5.63.
How big of a company is CymaBay Therapeutics?
CymaBay Therapeutics has a market capitalization of $386.79 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-72,550,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe.View Additional Information About CymaBay Therapeutics.
What is CymaBay Therapeutics' official website?
How can I contact CymaBay Therapeutics?
CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]
MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
